r/PharmAla_MDMA
Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech
globenewswire.comu/Firefly5647 — 2 days ago
How PharmAla Biotech Holdings Inc. is positioning APA-01 around traumatic brain injury and neurorehabilitation
pharmadevicenews.comu/Firefly5647 — 8 days ago
Genevieve Jurvetson (@gjurvetson) on X
“When Resilient submits its updated data to the FDA, I hope the FDA prioritizes the review. It is the only program with completed Phase 3 trials for PTSD and is positioned to begin treating patients immediately following approval.”
u/Firefly5647 — 10 days ago